*Five Years Citation in Google scholar (2016 - 2020) is. 1451*   *    IJPR IS INDEXED IN ELSEVIER EMBASE & EBSCO *       

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence
Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Remdesivir to Treat Novel Coronavirus (2019-nCoV)

Author: R. ANANDAN, S. THIRUMAL, B.S. DEEPAK
Abstract: Novel Coronavirus (2019-nCoV) or Human Coronavirus (HCoV) could be a new coronavirus that belongs to Betacoronaviruses type Human Coronaviruses, just like the Middle-East Respiratory Syndrome (MERS) coro-navirus and Severe Acute Respiratory Syndrome (SARS) coronavirus. Wuhan, the capital city of Hubei prov-ince, China recorded the primary case of this virus in December 2019. Until 27 March 2020, 10:00 CET, near 23,335 deaths were reported out of 509,164 confirmed cases recorded across the world. By the tip of January 2020, China confirmed that the COVID-19 transmitted from human to human. This study aims to check a completely unique medicament called “Remdesivir” (development code G S-5734) against the crystal structure of 2019-nCoV Main Protease. This study presents an ideal model for Remdesivir (anti-polymerase drug) to be tested in silico against 2019-nCoV Main Protease.
Keyword: Remdesivir, COVID-19, 2019-nC0V, Human Coronavirus.
DOI: https://doi.org/10.31838/ijpr/2020.12.02.252
Download: Request For Article
 




ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free